PTC Therapeutics, Inc.PTCTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating

Buy

15 analysts·Moderate coverage

67%

Rating Distribution

Strong Buy

00%

Buy

1067%

Hold

320%

Sell

213%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 11% higher.

Bear Case

$50.00

-34%

Consensus

$84.29

+11%

Bull Case

$119.00

+57%

Price Range15 analysts

Low

Consensus

High

$50.00

$119.00

Current Target

Current Price

$75.79

Upside to Target

$8.50

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.07(9 analysts)

P/E8x

Current: 8.2x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+22.21%

EPS—

FY2028

Rev+17.93%

EPS+174.72%

FY2029

Rev+20.14%

EPS+85.59%

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:+70.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Barclays

PTC Therapeutics assumed with Overweight from Equal Weight at Barclays

Target:$119.00

+57.6%from $75.49

Jan 8, 2026Morgan Stanley

PTC Therapeutics price target raised to $90 from $78 at Morgan Stanley

Target:$90.00

+16.5%from $77.24

Dec 1, 2025RBC Capital

PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Target:$91.00

+5.8%from $85.99

Nov 5, 2025Goldman Sachs

PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs

Target:$50.00

-30.4%from $71.79

Nov 5, 2025Wells Fargo

PTC Therapeutics price target raised to $93 from $73 at Wells Fargo

Target:$93.00

+37.3%from $67.72

Nov 5, 2025Barclays

PTC Therapeutics price target raised to $68 from $46 at Barclays

Target:$68.00

+0.4%from $67.72

Oct 28, 2025Jefferies

PTC Therapeutics price target raised to $77 from $63 at Jefferies

Target:$77.00

+13.5%from $67.86

Aug 8, 2025Robert W. Baird

PTC Therapeutics price target lowered to $70 from $72 at Baird

Target:$70.00

+54.3%from $45.38

May 7, 2025Robert W. Baird

PTC Therapeutics price target lowered to $66 from $70 at Baird

Target:$66.00

+82.4%from $36.19

Jan 7, 2025RBC Capital

PTC Therapeutics price target lowered to $58 from $63 at RBC Capital

Target:$58.00

+30.0%from $44.61

Nov 27, 2024Robert W. Baird

PTC Therapeutics (PTCT) PT Raised to $52 at Baird

Target:$52.00

+15.3%from $45.09

Oct 11, 2024Morgan Stanley

PTC Therapeutics price target raised to $45 from $32 at Morgan Stanley

Target:$45.00

+16.9%from $38.48

Aug 26, 2024UBS

UBS Upgrades PTC Therapeutics (PTCT) to Buy

Target:$47.00

+34.3%from $34.99

Jul 12, 2024Morgan Stanley

PTC Therapeutics price target raised to $32 from $30 at Morgan Stanley

Target:$32.00

-3.6%from $33.20

May 20, 2024Goldman Sachs

PTC Therapeutics (PTCT) PT Raised to $32 at Goldman Sachs, Reiterates Sell

Target:$32.00

-20.2%from $40.12

May 20, 2024Jefferies

PTC Therapeutics (PTCT) PT Raised to $46 at Jefferies

Target:$46.00

+15.5%from $39.81

Apr 26, 2024Morgan Stanley

Morgan Stanley Upgrades PTC Therapeutics (PTCT) to Equalweight

Target:$30.00

+5.0%from $28.57

Dec 14, 2022Goldman Sachs

Goldman Sachs Initiates Coverage On PTC Therapeutics with Sell Rating, Announces Price Target of $35

Target:$35.00

-10.1%from $38.94

Jun 23, 2022RBC Capital

PTC Therapeutics (PTCT) Stock: Why It Increased Over 4% Today

Target:$46.00

+20.1%from $38.29

Apr 5, 2022Cantor Fitzgerald

PTC Therapeutics (PTCT) Stock: Why The Price Increased

Target:$63.00

+44.4%from $43.64

Aug 31, 2021UBS

PTC Therapeutics price target lowered to $45 from $55 at UBS

Target:$45.00

+3.1%from $43.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance